Tech Company Financing Transactions
Laekna Therapeutics Funding Round
CS Capital, Infinity Capital and WorldStartup joined a $61 million Series D funding round for Laekna Therapeutics. The round was announced on 5/19/2022.
Transaction Overview
Company Name
Announced On
5/19/2022
Transaction Type
Venture Equity
Amount
$61,000,000
Round
Series D
Investors
Proceeds Purpose
The company intends to use the funds to accelerate its development efforts. Proceeds from the Series D financing will be used to accelerate the clinical development of Laekna's two core product candidates,
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5th Floor, No. 987, Cailun Road, Zhangjiang Hi-Tech Park, Pu
Shanghai, 201203
China
Shanghai, 201203
China
Phone
Website
Email Address
Overview
Founded in December 2016, Laekna Therapeutics is an emerging innovative biotech company based in Zhangjiang Pharma Valley in Shanghai, China and New Jersey, USA. It focuses on developing ground-breaking innovative therapies to treat cancer and liver diseases. Laekna Therapeutics is adopting a two-pronged strategy in new product development. The company enriches its pipeline by obtaining the global licenses of novel drug candidates in the clinical stage of development for which safety and anti-cancer efficacy have been assessed.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Chris Lu
Chief Medical Officer
Yong Yue
Chief Scientific Officer
Justin Gu
Browse more venture capital transactions:
Prev: 5/19/2022: DoraHacks venture capital transaction
Next: 5/19/2022: Dig Security venture capital transaction
Share this article
Where The Data Comes From
We report on funding rounds that are announced publicly. VC investment data records on this site are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs